Blog Archives
A study of drug management of neurobehavioural disorders in DMD
A team analysed the medical records (66 prescriptions) of 52 boys with Duchenne muscular dystrophy (DMD), aged 11 on average, who had received drug treatment for neurobehavioural disorders between 2008 and 2022 in two hospitals in Belgium and the Netherlands: the most common neurobehavioural disorders are attention disorders (64%), emotional and behavioural disorders (60%) and … [Read more]
Advances in congenital myopathies
Congenital myopathies are a heterogenous group of rare diseases characterised by structural abnormalities in muscle fibres which are most often detected at a young age. These abnormalities lead to muscle weakness (hypotonia and impaired motor skills) which generally manifests at birth or during the first few months of life (“congenital”). This document, presents research news … [Read more]
New tools for assessing the follow-up of two forms of muscular dystrophy
Monitoring, either as part of the usual follow-up of patients with muscular dystrophy or as part of clinical trials, is largely based on the use of functional scores: researchers report, in association with Duchenne muscular dystrophy (DMD) patient associations, the development of an upper limb function scale centred on the needs and feelings of patients … [Read more]
Significant drug iatrogenicity in late myasthenia gravis
A retrospective study of the medical data of 493 people suffering from autoimmune myasthenia followed by the university hospital centres of Strasbourg, Lyon, Grenoble and Angers reveals that the disease began after the age of 70 for 28% of them. Among these older patients : 76% improved with treatment during follow-up, despite lower doses, 41% … [Read more]
Results of the phase II-III trial of AMO-02 in congenital DM1
The results of the international REACH-CDM trial involving 56 children aged between 6 and 16 with the congenital form of myotonic dystrophy type 1 were announced in a press release on 6 September 2023. The primary endpoint, the Clinician-Completed Congenital DM1 Rating Scale, was not met. A significant reduction in CPK enzymes was measured in … [Read more]
Right heart involvement in DMD is a poor prognostic factor
A study of the respiratory and systolic functions of the right ventricle on Doppler echo in 90 young men with Duchenne muscular dystrophy (DMD), with a median age of 27.5 years and a median vital capacity of 10% of theoretical, showed : right ventricular systolic impairment in 46 (51%); the presence of left ventricular damage … [Read more]
Senolytic molecules improve the behaviour of muscle stem cells in DM1
In DM1, muscle stem cells adopt the characteristics of senescent cells, including the secretion of senescence-associated secretory phenotype (SASP). A Canadian team showed that : serum levels of certain SASPs (including interleukin 6) are correlated with muscle weakness and functional limitations. administration of a senolytic product inhibiting BCL-XL leads to the death of senescent myoblasts … [Read more]
Infantile myasthenia remains ocular and usually evolves favourably
A retrospective study of 859 patients followed by a Shanghai hospital for Myasthenia gravis diagnosed before the age of 14 found : an ocular form in 97.8% of cases, which only generalized in 14% of patients; 21.7% were in stable complete remission, 15.3% in pharmaceutical remission, and 42% of patients had achieved minimal manifestation status … [Read more]
Tofacitinib effective on dermatomyositis skin lesions, but not really on muscle
A Canadian team conducted a single-center study of 41 people with refractory myositis treated with tofacitinib after failure of four to five immunosuppressants: 23 had classical dermatomyositis, 12 an amyopathic form and 6 polymyositis; tofacitinib produced statistically and clinically significant skin improvement in the dermatomyositis group, but had no significant effect on muscle in all … [Read more]
MYOLOGY 2024: registration and submission of abstracts now open
The website for the 8th edition of the international congress dedicated to neuromuscular science MYOLOGY 2024, to be held in Paris from 22 to 25 April 2024, is now open. Abstracts can be submitted on the website until 30 November 2023. Registration is also open at the “early bird” rate until 31 December 2023. … [Read more]
